ArticleScientific reports2026
Association between LDL-R (exon 8 C.1171 G > A) polymorphisms and response to antiviral therapy in hepatitis C virus infection.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The entry of the hepatitis C virus (HCV) into liver cells is closely associated with its interaction with the low-density lipoprotein receptor (LDL-R), which plays a crucial role in facilitating viral uptake. This study aimed to investigate the association between the LDL-R (exon 8 C.1171 G/A) gene polymorphism and response to antiviral therapy in patients infected with HCV. Participants were divided into three groups. Group I included 30 patients positive for both anti-HCV antibodies and HCV-RNA who did not respond to antiviral therapy. Group II consisted of 60 patients positive for anti-HCV but negative for HCV-RNA, indicating successful treatment response. and Group III comprised 50 healthy individuals negative for both anti-HCV antibodies and HCV-RNA, serving as controls. Diagnostic assessments included reverse transcriptase-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and standard biochemical tests. Genotyping for LDL-R (exon 8 C.1171 G/A) polymorphisms was conducted using allele-specific PCR on patients from both the responder and non-responder groups. Of the 376 infected patients receiving antiviral therapy, 345 (91.8%) exhibited a positive response to treatment, whereas 31 (8.2%) did not. A total of 90 patients (60 responders and 30 non-responders) were included for genotypic analysis. Among responders, the A/A genotype of LDL-R (exon 8 C.1171 G > A) was the most prevalent (61.7%), whereas the G/G genotype was predominant among non-responders (76.7%). Genotyping analysis demonstrated that hepatitis C virus genotype 4 was the most common, being detected in all 20 responders and in 10 of 20 non-responders. These findings indicate a significant association between LDL-R (exon 8 C.1171 G/A) genetic variants and the response to antiviral therapy in Egyptian patients with chronic hepatitis C.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.